+612 9045 4394
PET for Drug Development and Evaluation : Developments in Nuclear Medicine - D. Comar

PET for Drug Development and Evaluation

Developments in Nuclear Medicine

By: D. Comar (Editor)

Hardcover Published: 1995
ISBN: 9780792337164
Number Of Pages: 360

Share This Book:


or 4 easy payments of $84.70 with Learn more
Ships in 15 business days

Earn 678 Qantas Points
on this Book

Other Available Editions (Hide)

  • Paperback View Product Published: 13th October 2012

Can drug development and evaluation be improved by the use of positron emission tomography (PET)? PET is now well established and many PET centres participate in networks that warrant the quality of their research. PET allows one to follow the effect of a drug on a variety of patients' metabolic parameters. In addition, PET may be used to follow the fate in vivo of a compound, allowing visualisation of its binding to specific receptors and a direct study of the mechanism of drug action in normal and pathological situations. The book shows the fields in which PET offers new and unique information for the development of drugs (conception, toxicity, pharmacokinetics and metabolism, clinical research, and relations between clinical and biological effects) and evaluates fields in which PET may shorten the development time of drugs. Audience: Professionals in the pharmaceutical industry in all areas of drug discovery and pharmacology, pre-clinical testing, pharmacokinetics and metabolism, clinical evaluation, registration and regulatory affairs. Government health authority representatives who assess data and documentation on new drug development and radiopharmaceuticals. Academic experts concerned with any of these areas.

Drug development and positron emission tomographyp. 1
Positron emission tomography: Basic principles and potential interest for pharmacological studiesp. 25
Is PET a tool for drug evaluation?p. 37
PET in neuropsychiatric drug developmentp. 51
Radioligand disposition and metabolism - Key information in early drug developmentp. 55
PET studies in the early clinical development of a new antipsychoticp. 67
PET in the development of Dopamine D1 antagonists as new potential antipsychotic drugsp. 73
Is the 5-HT[subscript 2]-receptor a target for antipsychotic drug action? PET studies on dopamine (D[subscript 2]) and serotonin (5-HT[subscript 2]) receptor occupancy in patients and healthy subjectsp. 83
Preclinical development of a radioligand for the study of central 5-HT[subscript 1A] receptors with PET-[11C]WAY - 100635p. 93
Comparative in vivo and in vitro selectivity of zolpidem for [omega] (Benzodiazepine) modulatory site subtypesp. 109
Do the effects of muscarinic receptor blockade on brain glucose consumption mimic the cortical and subcortical metabolic pattern of Alzheimer's disease in normal volunteers?p. 123
PET evaluation of drug treatment in ischemic stroke and Alzheimer's diseasep. 133
PET imaging of cerebral perfusion and oxygen metabolism in acute ischemic stroke: Implications for management and therapyp. 147
Pharmacokinetics: Kinetic modelling of MAO inhibitors and D[subscript 2] antagonistsp. 155
Brain activation under drug treatmentp. 167
Modifying the progression of Parkinson's diseasep. 179
COMT inhibition: Pharmacology of tolcapone and 6-[[subscript 18]F]-Fluoro-L-Dopa (FDOPA) PET resultsp. 189
Interaction of Lisuride with dopaminergic receptorsp. 197
Lisuride and [C-11]-raclopride interaction at the D2 receptor sitep. 205
Drug design in cardiology: The pharmaceutical industry point of viewp. 215
Myocardial receptors and their interaction with cardiovascular drugsp. 219
The pathophysiological background of cardiovascular diseases and its impact on diagnosis and treatmentp. 233
Effect of cardiotonic drugs on myocardial oxygen consumption and efficiency as assessed by [superscript 11]C-acetate and PETp. 253
Integration of new and classical techniques in drug development. PET application to Propionyl-L-carnitine pharmacokinetic studyp. 263
The view of the EORTC new drag development office on PET in (pre)clinical trials of anticancer drugsp. 267
Bottlenecks in anticancer drug discovery and development: In vivo pharmacokinetic and pharmacodynamic issues and the potential role of PETp. 277
Radiolabelled anticancer drugs for in vivo pharmacokinetic studies by PETp. 287
The use of radiolabelled anticancer drugs in phase I/II clinical trials and the assessment of therapeutic efficacy of new agents using PETp. 301
Kinetics and applications of F-18-fluorouracil in colorectal tumorsp. 327
The disposition of a new drug propellant (HFA 134a) in humans studied by fluorine-18 labelling and whole-body [gamma]-countingp. 341
Preclinical characterisation of radiolabelled idoxifenep. 353
Table of Contents provided by Blackwell. All Rights Reserved.

ISBN: 9780792337164
ISBN-10: 0792337166
Series: Developments in Nuclear Medicine
Audience: General
Format: Hardcover
Language: English
Number Of Pages: 360
Published: 1995
Country of Publication: NL
Dimensions (cm): 23.39 x 15.6  x 2.24
Weight (kg): 0.69

Earn 678 Qantas Points
on this Book